Health
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase1b/2 clin...
2025-09-05 16:46
1343
Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights...
2025-09-05 16:09
1574
/DISREGARD RELEASE: Angel Yeast/
We are advised by Angel Yeast that journalists and other readers should disregard the news release, Angel Yeast Protein Receives U.S. GRAS Certification, Opening the Door to Broader Access to Sustainable Protein, issued 04-Sep-2025 over PR Newswire, as the release contained erroneous information. ...
2025-09-05 12:36
2704
Smartee and Dental Monitoring Partner to Simplify Refinement Workflows for Orthodontists
SHANGHAI, Sept. 4, 2025 /PRNewswire/ -- Smartee Denti-Technology, a leading innovator in clear aligner solutions, and Dental Monitoring, the global leader in AI-powered remote monitoring for orthodontics, today announced a new integration designed to simplify and accelerate refinement workflows f...
2025-09-05 09:30
1507
Alma, a Sisram Medical Company, Announces Strategic Collaboration with Celebrity Skin Expert Nurse Jamie to Expand Global Consumer Presence
HONG KONG, Sept. 4, 2025 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions, today announced a strategic collaboration between its subsidiary Alma, a global leader in energy-based medical and aesthetic solutions, andJamie Sher...
2025-09-04 22:00
1587
Accro Bioscience to Present Phase II Data of AC-201 for Plaque Psoriasis at the European Academy of Dermatology & Venereology Congress 2025 in Paris
NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ -- Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced that it will present results from a Phase II clinical stu...
2025-09-04 20:24
1494
Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend
BEIJING, Sept. 4, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and six months ended Jun...
2025-09-04 18:00
4515
Global Bio Conference 2025 kicks off in Seoul, charting biotech's future
SEOUL, South Korea, Sept. 3, 2025 /PRNewswire/ -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety announced Wednesday that it kicked off Global Bio Conference 2025, under the theme "Bio, Navigating Infinite Possibilities." The conference will be held from...
2025-09-03 20:00
1591
Acer Expands SpatialLabs Pro Ecosystem with Immersive 3D Capabilities Across Multiple Verticals
Editor's Summary * Integration with NVIDIA Omniverse libraries via OpenXR runtime supports enhanced spatial awareness for industrial designs and simulations * Partnership with Video Engineering brings 3D stereo microscopy to inspection, design, and prototyping workflows * Collaboration with...
2025-09-03 17:40
1436
Acer Medical Unveils aiMed Ahead of IFA 2025, Showcasing the Future of AI in Healthcare
BERLIN, Sept. 3, 2025 /PRNewswire/ -- Acer Medical, an Acer Group company specializing in medical imaging and AI-powered healthcare solutions, unveiled aiMed, its next-generation generative AI medical documentation system at the next@acer global press conference, ahead ofIFA 2025 in Berlin. The mi...
2025-09-03 17:30
1692
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment ofJason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developin...
2025-09-03 10:52
1616
Desilo to Launch "HARVEST™," Encrypted Data Collaboration Platform for Healthcare, in December
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform,HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical c...
2025-09-02 21:00
1783
Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions h...
2025-09-02 21:00
1910
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data
* Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data * Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet...
2025-09-02 21:00
2147
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...
2025-09-02 20:30
3542
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...
2025-09-02 19:00
1586
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 /PRNe...
2025-09-02 18:00
1346
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
2025-09-02 17:52
1253
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...
2025-09-02 16:00
1308
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction
* AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success * 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics * 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the ...
2025-09-01 21:00
1418
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 295 media titles]
2025-11-29 09:00
Blackpanda and ST Engineering Partner to Strengthen Cyber Incident Response Across Asia
[Picked up by 287 media titles]
2025-12-03 14:27
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
[Picked up by 284 media titles]
2025-12-01 08:30Most Read
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2811
